John Lippincott

Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA.

AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green.

AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green.

Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA.

AlivaMab Discovery Services LLC is a private company that specializes in generating and screening large panels of antibodies to achieve their partners' design goals. AlivaMab Discovery Services is based in San Diego, CA. The company focuses on delivering antibodies that are characterized for function, kinetics, and developability, and engineering for advanced modalities, including multispecifics and cars. The company has experience in antibody drug discovery and development from many of the world's top pharmaceutical companies, including AbbVie, AstraZeneca, Bristol Myers Squibb, Novartis, Pfizer, and Roche/Genentech. The company was founded by John Lippincott, and the CEO is Larry L. Green.

Ablexis LLC develops next-generation platform for antibody drug discovery. It develops the AlivaMab Mouse, an innovative, next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies. The company was founded by Green L. Larry and Hiroaki Shizuya in December 2009 and is headquartered in Burlingame, CA.